seed
Stage
About
EvlaBio develops a selective monoclonal antibody that inhibits FGFR4 to prevent left ventricular hypertrophy caused by aberrant FGF23-FGFR4 signaling in patients with chronic kidney disease.
Explore EvlaBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.